Rabeprazole Sodium Delayed Release Tablets
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Amendment 0005 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets extends the closing date until April 23, 2020 at 3:00 DST and to update email submissions of offers.
Amendment 0004 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets closing date extended until April 16, 2020 at 3:00 DST to allow email submissions of offers.
Amendment 0003 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets closing date extended until April 09, 2020 at 3:00 PM DST.
Amendment 0002 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets to incoproate three (3) DFARS clauses into solicitation.
Amendment 0001 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets to incorporate two (2) DFARS clauses into solicitation.
Solicitation for Rabeprazole Sodium DR Tablets SPE2D2-20-R-0061.